Rakuten Medical reports preclinical results with PD-L1-targeted photoimmunotherapy
Sep. 20, 2024
Rakuten Medical Inc. has presented preclinical results with RM-0256, a PD-L1-targeted photoimmunotherapy, showing its ability to kill immunosuppressive myeloid cells to activate local and systemic antitumor immunity.